NCT00505843View on ClinicalTrials.gov

A Study of MK0657 in Parkinson's Disease Patients (0657-006)

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
Parkinson's Disease
Interventions
DRUG

MK0657

7mg MK0657 capsules

DRUG

Comparator: Placebo (unspecified)

7mg MK0657 Pbo capsules

DRUG

Comparator: levodopa

levodopa \>/=1.0 mg/kg/hr dose of levodopa. levodopa infusions will occur over a 2 hour period

DRUG

Comparator: carbidopa

carbidopa 25mg administered 3 times: at 1 hour before levodopa infusion and at 1 and 3 hours after the start of levodopa infusion.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00505843 - A Study of MK0657 in Parkinson's Disease Patients (0657-006) | Biotech Hunter | Biotech Hunter